Fibromiyalji ve aynı zamanda konstipasyon baskın irritabl barsak sendromu olan olgularda tegaserodun ağrı semptomu üzerine etkisi
Abstract
Özet
Amaç. Bu çalışmanın amacı bir 5HT4 agonisti olan tegaserodun fibromyalji sendromlu hastalardaki ağrı üzerine etkisini incelemektir. Yöntem. Mart-Eylül 2005 arası hastanemize başvuran ve kabızlık baskın irritabl barsak sendromu ile beraberinde fibromyalji tanısı alan 28 kadın hasta çalışmaya alındı. Hastalar alarm semptomları açısından sorgulandı ve organik hastalığı dışlamak için gerekli tetkikleri yapıldı. Hastalara tegaserod 6 mg tablet sabah akşam yemekten 30 dk önce şeklinde tedavi başlandı. Hastalar tedavinin 1. ve 2. ayı sonunda kontrole çağrıldılar. Ağrı şiddetinin belirlenmesi için visual analog skala (VAS) kullanıldı. Bulgular. Hastaların tedavinin 1. ve 2. ayı sonundaki VAS değerleri tedavi öncesine göre düşüş göstermiştir. Değerler karşılaştırıldığında aralarındaki farklılık önemli bulunmuştur (p<0,05). Sonuç. IBS ve fibromyalji ortak etyopatogeneze sahip hastalıklardır; ancak tegaserodun piyasadan kaldırılmış olması bu konuda daha geniş çaplı çalışma yapılmasını kısıtlamaktadır.
Anahtar kelimeler: İrritabl barsak sendromu, fibromyalji, tegaserod
Abstract
Aim.The aim of this study is to investigate the effect of tegaserod which is a the 5HT4 agonist on the symptom of pain in patients with fibromyalgia syndrome. Methods. Twenty-eight female patients who applied to our hospital between March and September 2005 and were diagnosed as constipation-dominant irritable bowel syndrome with fibromyalgia were included in the study. The patients were asked about alarm symptoms and the necessary tests were done to exclude any organic disease. The patients received tegaserod 6 mg tablet 30 min before breakfast and dinner and they were called to their control visits after one and two months of therapy. Visual analog scale (VAS) was used to determine the intensity of pain. Result. The VAS values of the patients after the first and second months decreased significantly (p<0.05) Conclusion: IBS and fibromyalgia are diseases that share the common ethiopathogenesis; but, there is a limitation in planning studies with larger number of patients in this subject as tegaserod has been taken out from the market.
Keywords: Irritable bowel syndrome, fibromyalgia, tegaserod
Keywords
References
- Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002; 28: 181–199.
- Clauw D. Fibromyalgia. In: Ruddy S, Haris E, Sledge C, editors: Kelley’s Textbook of Rheumatology.7th ed. Philadelphia: WB Saunders. 2001. p. 417-427.
- Harris RE, Clauw DJ. Newer treatments for fibromyalgia syndrome. Ther Clin Risk Manag 2008; 4: 1331-42.
- Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999; 94: 3541-6.
- Kurland JE, Coyle WJ, Winkler A, Zable E. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci 2006; 51: 454-60.
- Yunus MB, Inanici F, Aldag JC, Mangold RF. Fibromyalgia in men: comparison of clinical features with women. J Rheumatol 2000; 27: 485–490.
- Wagstaff AJ, Frampton JE, Croom KF. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.. Drugs 2003; 63:1101-1120.
- Schmitt C, Krumholz S, Tanghe J. The partial 5-HT4 receptor partial agonist tegaserod (HTF 919) improves abdominal discomfort/pain and normalises altered bowel function in irritable bowel syndrome (IBS). Gut 1999; 45: A258.
- Novick J, Miner P, Krause R. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-1888.
- Carr AJ, Higginson IJ. Are quality of life measures patient centred? BMJ 2001; 322: 1357-60.
- Gur A, Cevik R, Nas K, Sarac AJ, Ozen S. Quality of life in young fibromyalgia patients and effect of depression. APLAR J Rheumatol 2006; 9: 70–78.
- Burckhardt CS, Clark SR, Bennett RM, Fibromyalgia and quality of life: a comperative analysis. J Rheumatol 1993; 20: 475-9.
- Bernard AL, Prince A, Edsall P. Quality of life issues for in fibromyalgia patients. Arthritis Care Res 2000; 13: 42-50.
- Färber L, Stratz T, Brückle W, Spath M, Pongratz D,Lautenschlager J. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5- HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol 2000; Suppl 113: 49-54.
- Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study. Clin Rheumatol 2000; 19: 6- 8.
- Haus U, Varga B, Stratz T, Spath M, Müler W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000; Suppl 113: 55-8.
- Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double- blind, placebo-controlled trial. J Rheumatol 2009; 36:398-409.
Fibromiyalji ve aynı zamanda konstipasyon baskın irritabl barsak sendromu olan olgularda tegaserodun ağrı semptomu üzerine etkisi
Abstract
Amaç. Bu çalışmanın amacı bir 5HT4 agonisti olan tegaserodun fibromyalji sendromlu hastalardaki ağrı üzerine etkisini incelemektir. Yöntem. Mart-Eylül 2005 arası hastanemize başvuran ve kabızlık baskın irritabl barsak sendromu ile beraberinde fibromyalji tanısı alan 28 kadın hasta çalışmaya alındı. Hastalar alarm semptomları açısından sorgulandı ve organik hastalığı dışlamak için gerekli tetkikleri yapıldı. Hastalara tegaserod 6 mg tablet sabah akşam yemekten 30 dk önce şeklinde tedavi başlandı. Hastalar tedavinin 1. ve 2. ayı sonunda kontrole çağrıldılar. Ağrı şiddetinin belirlenmesi için visual analog skala (VAS) kullanıldı. Bulgular. Hastaların tedavinin 1. ve 2. ayı sonundaki VAS değerleri tedavi öncesine göre düşüş göstermiştir. Değerler karşılaştırıldığında aralarındaki farklılık önemli bulunmuştur (p
Keywords
References
- Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002; 28: 181–199.
- Clauw D. Fibromyalgia. In: Ruddy S, Haris E, Sledge C, editors: Kelley’s Textbook of Rheumatology.7th ed. Philadelphia: WB Saunders. 2001. p. 417-427.
- Harris RE, Clauw DJ. Newer treatments for fibromyalgia syndrome. Ther Clin Risk Manag 2008; 4: 1331-42.
- Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999; 94: 3541-6.
- Kurland JE, Coyle WJ, Winkler A, Zable E. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci 2006; 51: 454-60.
- Yunus MB, Inanici F, Aldag JC, Mangold RF. Fibromyalgia in men: comparison of clinical features with women. J Rheumatol 2000; 27: 485–490.
- Wagstaff AJ, Frampton JE, Croom KF. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.. Drugs 2003; 63:1101-1120.
- Schmitt C, Krumholz S, Tanghe J. The partial 5-HT4 receptor partial agonist tegaserod (HTF 919) improves abdominal discomfort/pain and normalises altered bowel function in irritable bowel syndrome (IBS). Gut 1999; 45: A258.
- Novick J, Miner P, Krause R. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-1888.
- Carr AJ, Higginson IJ. Are quality of life measures patient centred? BMJ 2001; 322: 1357-60.
- Gur A, Cevik R, Nas K, Sarac AJ, Ozen S. Quality of life in young fibromyalgia patients and effect of depression. APLAR J Rheumatol 2006; 9: 70–78.
- Burckhardt CS, Clark SR, Bennett RM, Fibromyalgia and quality of life: a comperative analysis. J Rheumatol 1993; 20: 475-9.
- Bernard AL, Prince A, Edsall P. Quality of life issues for in fibromyalgia patients. Arthritis Care Res 2000; 13: 42-50.
- Färber L, Stratz T, Brückle W, Spath M, Pongratz D,Lautenschlager J. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5- HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol 2000; Suppl 113: 49-54.
- Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study. Clin Rheumatol 2000; 19: 6- 8.
- Haus U, Varga B, Stratz T, Spath M, Müler W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000; Suppl 113: 55-8.
- Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double- blind, placebo-controlled trial. J Rheumatol 2009; 36:398-409.
Details
| Primary Language | English |
|---|---|
| Journal Section | Medical Science Research Articles |
| Authors | |
| Publication Date | March 17, 2009 |
| Published in Issue | Year 2009Volume: 31 Issue: 2 |